TWIST1 and acute myeloid leukemia: The observation of Twist1-imposed clinical benefits could be extended to survival outcome, as Twist1-overexpressing AML patients had a significantly longer overall survival than their counterparts did (log-rank test, P=0.033, Figure 4a).